We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Genedata and Nonlinear Co-Market Solution for High-throughput Protein-gel Processing

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Nonlinear Dynamics Ltd and Genedata AG have announced that they have entered a co-marketing agreement to promote synergies between their Progenesis and Expressionist solutions.

Under the terms of the agreement, Nonlinear Dynamics and Genedata are collaborating to create an integrated workflow between these respective systems.

“With this agreement we show our commitment to industrial-scale proteomics research,” explained Adesh Kaul, head of the Expressionist business unit at Genedata AG.

The combined solution delivers additional result validation preceding the final MS identification and sample classification stages of the gel-based workflow.

Employing supplementary statistical processing to Progenesis 2D gel image analysis data, researchers are able to further corroborate findings and proceed to spot picking with greater confidence.

Kaul adds, “By automating the exchange of data between Progenesis and Expressionist, we are providing a high-throughput workflow for this otherwise time-consuming and error-prone task.”

John Spreadbury, Group Sales and Marketing Director at Nonlinear Dynamics and CEO of Nonlinear USA Inc., added, “This agreement has been demand-led, with shared customers promoting to Genedata and Nonlinear the combined power of this integrated solution.”

“We are always keen to talk to companies with whom we can broker these mutually beneficial arrangements, since it is in the end to the advantage of our customer base.”

“We are looking forward to working with Genedata to help our customers achieve a greater body of statistical data with which to drive their proteomics research.”